LogicBio Therapeutics (LogicBio Therapeutics) Cash-to-Debt : 3.50 (As of Jun. 2022)

View and export this data going back to 2018. Start your Free Trial

What is LogicBio Therapeutics Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. LogicBio Therapeutics's cash to debt ratio for the quarter that ended in Jun. 2022 was 3.50.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, LogicBio Therapeutics could pay off its debt using the cash in hand for the quarter that ended in Jun. 2022.

The historical rank and industry rank for LogicBio Therapeutics's Cash-to-Debt or its related term are showing as below:

LOGC's Cash-to-Debt is not ranked ^*
in the Biotechnology industry.
Industry Median: 6.49
* Ranked among companies with meaningful Cash-to-Debt only.

LogicBio Therapeutics Cash-to-Debt Historical Data

The historical data trend for LogicBio Therapeutics's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

LogicBio Therapeutics Cash-to-Debt Chart

LogicBio Therapeutics Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Cash-to-Debt

Get a 7-Day Free Trial

No Debt

4.91

4.36

4.04

LogicBio Therapeutics Quarterly Data
	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22
Cash-to-Debt	Get a 7-Day Free Trial															4.43	4.16	4.04	3.51	3.50

Competitive Comparison of LogicBio Therapeutics's Cash-to-Debt

For the Biotechnology subindustry, LogicBio Therapeutics's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

LogicBio Therapeutics's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, LogicBio Therapeutics's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where LogicBio Therapeutics's Cash-to-Debt falls into.

LogicBio Therapeutics Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

LogicBio Therapeutics's Cash to Debt Ratio for the fiscal year that ended in Dec. 2021 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	53.48	/	(4.522	+	8.731)
	=	4.04

LogicBio Therapeutics's Cash to Debt Ratio for the quarter that ended in Jun. 2022 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	38.846	/	(4.6	+	6.487)
	=	3.50

LogicBio Therapeutics (NAS:LOGC) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

LogicBio Therapeutics Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of LogicBio Therapeutics's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

LogicBio Therapeutics (LogicBio Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » LogicBio Therapeutics Inc (NAS:LOGC) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

65 Hayden Avenue, 2nd Floor, Lexington, MA, USA, 02421

Website

https://www.logicbio.com

LogicBio Therapeutics Inc is a genome editing company focused on developing medicines to durably treat rare diseases in patients with significant unmet medical need using GeneRide, its proprietary technology platform. Its product candidates include LB-001, LB-101, LB-201 and LB 301.

Executives

Mark J Enyedy	director	C/O FATE THERAPEUTICS, INC., 3535 GENERAL ATOMICS COURT, SUITE 200, SAN DIEGO CA 92121
Mariana Nacht	officer: Chief Scientific Officer	65 HAYDEN AVENUE, 2ND FLOOR, LEXINGTON MA 02421
Daniel Gruskin	officer: Chief Medical Officer	65 HAYDEN AVENUE, 2ND FLOOR, LEXINGTON MA 02421
Susan Kahn	director	65 HAYDEN AVENUE, 2ND FLOOR, LEXINGTON MA 02421
Joshua Blacher	officer: Interim CFO	65 HAYDEN AVENUE, 2ND FLOOR, LEXINGTON MA 02421
Andrea Paul	officer: General Counsel and Secretary	65 HAYDEN AVENUE, 2ND FLOOR, LEXINGTON MA 02421
Frederic Chereau	director, officer: See Remarks	C/O ATYR PHARMA, INC., 3545 JOHN HOPKINS COURT, SUITE 250, SAN DIEGO CA 92121
Kyle Chiang	officer: Chief Operating Officer	65 HAYDEN AVENUE, 2ND FLOOR, LEXINGTON MA 02421
Cecilia Jones	officer: Chief Financial Officer	C/O LOGICBIO THERAPEUTICS, INC., 65 HAYDEN AVENUE, 2ND FLOOR, LEXINGTON MA 02421
Jonathan Quick	officer: Senior Director-Finance	C/O LOGICBIO THERAPEUTICS, INC., 65 HAYDEN AVENUE, 2ND FLOOR, LEXINGTON MA 02421
Jeff Goater	director	C/O SURFACE ONCOLOGY, INC., 50 HAMPSHIRE STREET, 8TH FLOOR, CAMBRIDGE MA 02139
Daphne Karydas	director	35 GATEHOUSE DRIVE, BUILDING D, FLOOR 3, WALTHAM MA 02451
Erez Chimovits	director	P.O. BOX 4023, HERZLIYA PITUACH L3 4614001
Orbimed Advisors Llc	director, 10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Orbimed Genesis Gp Llc	director, 10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022